What if I get a placebo?

raymond.vanderwaal@mytomorrows.com 11 Jan 2024

1 mins read

share this post

Placebos are not normally used in clinical trials for patients with cancer or other serious conditions. Instead of using a placebo, these clinical trials use a standard treatment. A standard treatment is the approved drug that is currently used to treat the disease and considered to be the most effective option available. So, patients receive either the new treatment or the standard treatment. Placebos are used in cases where there is no standard treatment for a condition. A placebo is designed to look the same as the drug being tested (but it does not contain any medicine).

share this post

raymond.vanderwaal@mytomorrows.com 11 Jan 2024

more articles

view all blogs

Michel van Harten AWS Pioneers

myTomorrows Joins AWS Pioneers Project 2026

myTomorrows Team

18 Mar 2026

7 mins read

myTomorrows Trust Center blog

myTomorrows Trust Center: Security, Compliance, and Transparency

Filippo Mandrini

19 Feb 2026

9 mins read

Man with ALS performing physical therapy

The Role of Physical Therapy in ALS Care

Andrea Enguita

14 Jan 2026

16 mins read

Medical researchers

Sentynl Selects myTomorrows to Lead Managed Access Program

myTomorrows Team

15 Dec 2025

4 mins read

Whitepaper: Advancing Neuro-Oncology Clinical Trial Access

Daniël Groeneweg

27 Nov 2025

8 mins read

Person with end-stage Parkinson's and caregiver

End-Stage Parkinson’s Disease: Symptoms, Care, and Support

Andrea Enguita

18 Nov 2025

21 mins read

Getting Started: myTomorrows Referral Platform for Site Staff

Adrianne Rivard

14 Nov 2025

10 mins read

myTomorrows Avego finding announcement

Our next chapter: €25M growth investment to scale patient access worldwide

Michel van Harten

11 Nov 2025

7 mins read

ALS patient flow

Accelerating ALS Clinical Trial Recruitment in the U.S.

Dennis Akkaya

10 Oct 2025

12 mins read

Vanessa Lemarie

myTomorrows’ COO Vanessa Lemarié Named in Sifted’s Top 100 Women in Tech Europe

Michel van Harten

10 Oct 2025

2 mins read